Pharmaceutical company Acer Therapeutics has partnered with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride for the potential treatment of Covid-19 patients.
Under the research collaboration agreement, the partners will work together to speed-up the clinical development of emetine, which showed broad and potent antiviral activity in preclinical and clinical studies.
Currently, Acer Therapeutics is in discussions with the US Food and Drug Administration (FDA)’s Division of Antivirals (DAV) following initial responses to its pre-investigational new drug (pre-IND) filing.